Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Drugs Made In America Acquisition Corp. Units (DMAAU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: DMAAU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 |
52 Weeks Range 10.00 - 124.00 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Units
Company Overview
History and Background
Drugs Made In America Acquisition Corp. Units is a blank check company, also known as a special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Core Business Areas
- Acquisition: Searching for a target company to merge with or acquire. SPACs do not have specific operations until acquiring a target company.
Leadership and Structure
Leadership typically includes a CEO, CFO, and a board of directors. The organizational structure is designed to facilitate the identification and acquisition of a target company.
Top Products and Market Share
Key Offerings
- Units: Units consist of one share of Class A common stock and one-half of one redeemable warrant. The value lies in the potential acquisition of a company. The value is largely speculative before the acquisition.
Market Dynamics
Industry Overview
The SPAC market is highly competitive, with numerous SPACs seeking acquisition targets across various industries. Regulatory scrutiny and market sentiment can significantly impact SPAC performance.
Positioning
Drugs Made In America Acquisition Corp. Units positions itself as a vehicle for a private company to go public through a reverse merger. Their competitive advantage lies in their management team's expertise and network.
Total Addressable Market (TAM)
The TAM depends on the sectors they are willing to invest in. The market is very large ($100s of billions) but it will only be a small part of that once an acquisition is completed.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to capital through IPO
- Potential for high returns if a successful acquisition is made
Weaknesses
- Limited operating history
- Dependence on finding a suitable target
- Potential for conflicts of interest
- Dilution from warrants
Opportunities
- Growing demand for alternative investment vehicles
- Increasing number of private companies seeking to go public
- Potential for synergies with acquired company
Threats
- Increased competition from other SPACs
- Regulatory changes impacting SPACs
- Market volatility impacting deal valuations
- Inability to find a suitable target
Competitors and Market Share
Key Competitors
Competitive Landscape
Competitive landscape involves other SPACs searching for targets in the same industry.
Growth Trajectory and Initiatives
Historical Growth: N/A before acquisition
Future Projections: Growth depends entirely on the acquired company's performance.
Recent Initiatives: Focus is on identifying and evaluating potential acquisition targets.
Summary
Drugs Made In America Acquisition Corp. Units is a SPAC with no operating history, making it a speculative investment. Its success hinges on finding a suitable acquisition target and executing a successful merger. The company faces significant competition and regulatory risks. The value of the unit is determined by the success of acquisition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Outlets
Disclaimers:
Information is based on available data and may not be complete. This is not financial advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Units
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-01-28 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.